THE European Medicines
Agency’s Committee for Medicinal
Products for Human Use (CHMP)
has recommended ten new
medicines for approval.
The additions include the first two
monoclonal antibody biosimilars,
Remsima and Inflectra with the
same indication as Remicade,
as well as 3 cancer therapies:
Provenge, Tafinlar and Stivarga.
Also approved are Procysbi for
the management of cystinosis and
Lemtrada for MS.
The remaining recommendations
were for Cholib for reduction of CV
risk, Nexium Control for reflux and
Evarrest for haemostasis.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Jul 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.